Psilocybin-Research.comSearchable psilocybin and psilocin bibliometrics.
Published

Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT Formulations

Emerging psychedelic therapeutics increasingly rely on mechanistic precision, receptor selectivity, and pharmacokinetic control. Recent inventions introduce simplified iboga analogs with tunable polypharmacology, real-time EEG biomarkers that individualize psilocybin dosing, and standardized harmine-DMT ratios with high bioavailability. Together, these innovations form a coherent framework for safer, more reliable, and clinically actionable psychedelic medicines.

Open source BibTeX RIS

Bibliographic context

Journal
ACS Medicinal Chemistry Letters
Date
2025-12-15
Source
OpenAlex
DOI
10.1021/acsmedchemlett.5c00714
PubMed
41531985

Authors

Anna C. RennerRobert B. Kargbo
Watch author

Topics and keywords

psilocybin Brain ImagingPharmacologyReceptor PharmacologyBiomarkersToxicity Other PsilocybinMedicineComputer scienceElectroencephalographyHallucinogenNeurosciencePharmacologyInvestigational DrugsPsychologyMEDLINEPsychedelics and Drug StudiesForensic Toxicology and Drug AnalysisCannabis and Cannabinoid Research

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT Formulations2025-12-15

Related papers

Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic PotentialDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticityTranslational Psychiatry · 2026-06-04Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-05-31Psilocybin-induced neurocardiogenic syncope: a case reportPsychopharmacology · 2026-05-27The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising ApproachDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapyNatural Product Research · 2026-06-01